# DoD Bone Marrow Failure Investigator-Initiated Research Award

Source: https://welltoldgrants.com/grants/ht9425-23-bmfrp-iira-dod-bone-marrow-failure-investigator-initiated-research/  
Official notice: https://www.grants.gov/search-results-detail/347684

> Defense Health Agency Contracting Activity - DHACA offered grants to any type of organization. It expected to make about 2 awards worth $2.4 million in total. Applications closed on September 20, 2023.

| Field | Value |
|---|---|
| Opportunity number | HT9425-23-BMFRP-IIRA |
| Agency | Defense Health Agency Contracting Activity - DHACA |
| Status | Forecast |
| Deadline | September 20, 2023 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | 2 |
| Total funding | $2.4 million |
| Cost sharing | not required |
| Assistance Listings | 12.420 |

## Who can apply

- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

## What the grant funds

The FY23 BMFRP IIRA will offer two funding levels with different intent: Funding Level 1 (FL1): To support studies that further develop mature ideas, expand upon key discoveries, and have the potential to make significant advances in research and/or patient care in the FY23 BMFRP Focus Areas. IIRA applications may involve translational and clinical research including studies in animal models, research with human data and/or anatomical substances, and research with human subjects, as well as correlative studies associated with an existing clinical trial; however, FL1 awards may not be used to support a clinical trial. Multidisciplinary collaborations are encouraged. Funding Level 2 (FL2): To support Investigational New Drug (IND) application-enabling efforts. The BMFRP recognizes the scientific and financial challenges associated with advancing promising, potentially life-changing, therapeutic agents from the laboratory to clinical evaluation. Data related to lead compound characterization; formulation and stability; absorption, distribution, metabolism and excretion; dose/response; and toxicology are required before clinical trials can commence. The proposed studies under the FL2 IND-enabling efforts are expected to be empirical in nature, product-driven, and focused on the accumulation of data for a lead therapeutic candidate that will be included in an IND application submission to the U.S. Food and Drug Administration (FDA). At least one and no more than three lead therapeutic candidates must be named at the time of application submission to meet the intent of the FL2 mechanism. Library screening or drug optimization studies do not meet the intent of FL2. The intent of FL2 awards is to perform the necessary evaluation of promising therapies that will lead to clinical trials; however, clinical trials themselves are not supported by this mechanism. FL2 applications must address the FY23 BMFRP Focus Area, “Find effective BMF treatments and cures.”

## Questions people ask

### Is HT9425-23-BMFRP-IIRA still open?

No. It closed on September 20, 2023. A newer notice is open: HT942526BCRPCREA2, closes November 18, 2026 (11 days left).

### Who can apply for DoD Bone Marrow Failure Investigator-Initiated Research Award?

Defense Health Agency Contracting Activity - DHACA accepted applications from any type of organization.

### What is the deadline for DoD Bone Marrow Failure Investigator-Initiated Research Award?

Closed September 20, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

About $2.4 million in total across about 2 awards.

### Who has won Military Medical Research and Development grants before?

The largest recipients over five fiscal years were The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Univeristy of Texas M.D. Anderson Cancer Center, The Johns Hopkins University. The program made 5,470 awards worth $6.9 billion in that time.